Navigation Links
Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
Date:5/3/2011

ALLEGAN, Mich., May 3, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 26, 2011.

Perrigo's Chairman and CEO Joseph C. Papa commented, "We are very pleased with this quarter's record revenue and earnings performance. The main contributors to this strong performance were $44 million of new product sales, continued operational execution in our Rx and API segments and another solid quarter in Nutritionals. In Consumer Healthcare, revenue grew 13% in the quarter as we continue to see very strong demand for our products. At the same time, we have been experiencing some throughput pressure in manufacturing, but we are in the process of making investments that we believe will enhance output in the near future."

Mr. Papa continued, "The April resolution of the 2010 FDA warning letter in less than one year is a major achievement. We are convinced that this process has made us a better company, as it helped us to further enhance the quality of our production. Our retailers and consumers continue to realize the value proposition of Perrigo's high quality, affordable healthcare products and we look forward to increasing our production volumes further to meet their growing demand."  

Refer to Table I at the end of this press release for adjustments in the current year and prior year periods and additional non-GAAP disclosure information.

The Company's reported results are summarized in the attached Condensed Consolidated Statements of Income, Balance Sheets and Statements of Cash Flows.

Perrigo Company(from continuing operations, in thousands, except per share amounts)(see the attached Table I for reconciliation to GAAP numbers)Third Quarter

Nine Months2011

2010

2011

2010Net Sales

$691,563

$537,632

$2,050,400

$1,648,390Repor
'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam
2. Perrigo Company Announces Quarterly Dividend
3. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
4. Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
5. Perrigo Announces Conclusion of the FDA Re-Inspection
6. Perrigo Company to Present at the Barclays Capital 2011 Global Health Care Conference
7. Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
8. Perrigo Company to Present at the Citi 2011 Global Health Care Conference
9. Perrigo Confirms Filing for Generic Version of Taclonex® Ointment and Announcement of Lawsuit by Leo Pharma
10. Perrigo Enters Into Exclusive Sales and Distribution Agreement With AgaMatrix for Store Brand Blood Glucose Monitoring Products
11. Perrigo Announces Settlement of Rogaine® Foam Patent Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... Drug safety remains front and center for the U.S. ... improve the public,s perception of the organization. Likewise, the ... consumers and recognizes that its diligence in the reporting ... effort. One issue that is impacting both ...
... 28, 2011 VirtualScopics, Inc. (Nasdaq: VSCP ), ... announced that before the market opens on Thursday, February 24, ... 2010 financial results. The company will host a conference call ... President and Chief Executive Officer, Jeff Markin, and Chief Business ...
Cached Medicine Technology:Navigating the Gray Areas of Post-Marketing Surveillance 2VirtualScopics Schedules Fourth Quarter/Full Year 2010 Earnings Announcement 2
(Date:4/18/2014)... University psychologists have made a brain-related discovery that ... disorders. , This discovery opens up the possibility ... suppress a specific brain activity that the researchers ... The Journal of Neuroscience has just ... McDonald, an associate professor of psychology and his ...
(Date:4/17/2014)... non-cancerous prostate tissue may have nearly twice the risk ... inflammation, according to results of a new study led ... , The link between persistent inflammation and cancer was ... those with a Gleason score between 7 and ... and rapidly growing prostate cancers. , "What we,ve shown ...
(Date:4/17/2014)... of Experimental Biology and Medicine a ... and Paul Kenis in the Institute of Genomic ... of Illinois Urbana-Champaign describe their recent work on ... variety of cell functions including energy metabolism, signaling, ... in regulating normal cellular behavior, redox status has ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... ... ... ... ...
... ... ... ... ...
... compared traditional surgery with less-invasive stenting to clear dangerously ... "seminal and robust." The Carotid Revascularization Endarterectomy vs. ... of both procedures are roughly equal. The trial, conducted ... the largest randomized stroke prevention trials ever. Loyola ...
... ... Conducts Statewide Outreach Efforts to Provide Low-Income Children Access to Dental Care ... ... Month draws to a close, California’s dental hygienists are reminding parents and ...
... 12,000 years ago, researchers say, , FRIDAY, Feb. 26 (HealthDay ... East more than 12,000 years ago, new research suggests. , ... IGF1 is a major determinant of small size in dogs. ... domestication of the Middle Eastern gray wolf, according to the ...
... evidence that newcomers hold mettle against warfarin, aspirin , ... more proof that the mainstays of anti-clotting therapy, namely ... newcomers. , Researchers presenting their findings during a ... meeting in San Antonio show that one new drug, ...
Cached Medicine News:Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 2Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 3Health News:High Representative Ashton and Commissioner Georgieva to Visit Haiti 4Health News:American National Announces Corrected Dividend Dates 2Health News:Stents as good as surgery for clogged carotid arteries 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 2Health News:California Dental Hygienists Say National Children's Dental Health Month Should Be a Yearlong Effort 3Health News:Current Blood Thinners Face Tough Competition 2Health News:Current Blood Thinners Face Tough Competition 3
... of infrared laser photocoagulators includes the OcuLight ... lasers serve as a single laser source ... no regular maintenance or special electrical/cooling, and ... The OcuLight SLx is now available with ...
The simplest, most accurate Ortho-K lens fitting system ever!...
... permeable contact lenses used for corneal refractive ... (myopia). The patient wears the lenses overnight ... During the day, nearsightedness is corrected or ... RG contact lenses apply slight pressure to ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
Medicine Products: